Home4547 • TYO
add
Kissei Pharmaceutical Co Ltd
Previous close
¥3,690.00
Day range
¥3,650.00 - ¥3,730.00
Year range
¥3,000.00 - ¥4,270.00
Market cap
175.35B JPY
Avg Volume
79.26K
P/E ratio
13.78
Dividend yield
2.35%
Primary exchange
TYO
Market news
Financials
Income Statement
Revenue
Net income
| (JPY) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 23.20B | 11.12% |
Operating expense | 9.26B | 14.14% |
Net income | 3.59B | 35.05% |
Net profit margin | 15.48 | 21.60% |
Earnings per share | — | — |
EBITDA | 3.52B | 10.84% |
Effective tax rate | 18.37% | — |
Balance Sheet
Total assets
Total liabilities
| (JPY) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 44.46B | 2.90% |
Total assets | 248.93B | 8.96% |
Total liabilities | 37.61B | 21.87% |
Total equity | 211.32B | — |
Shares outstanding | 42.81M | — |
Price to book | 0.75 | — |
Return on assets | 2.41% | — |
Return on capital | 2.83% | — |
Cash Flow
Net change in cash
| (JPY) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 3.59B | 35.05% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Founded
Aug 9, 1946
Headquarters
Website
Employees
1,779
